Yan Xiao1, Ying-Kun Ren2, Hui-Jun Cheng1, Li Wang1, Su-Xia Luo3. 1. Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) Zhengzhou 450008, China. 2. Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) Zhengzhou 450008, China. 3. Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) Zhengzhou 450008, China.
Abstract
OBJECTIVES: There is increasing evidence that the presence of an inflammation-based prognostic score (modified Glasgow prognostic score, mGPS) could predict survival in patients with advanced cancer. The aim of this study was to investigate the prognostic value of mGPS in patients with cervical cancer. METHODS: We included 238 consecutive patients with cervical cancer in our study. The albumin and serum C-reactive protein (CRP) were measured before initiation of treatment. The relationships between the mGPS and other clinical parameters including body mass index (BMI), white blood cell count, lymphocyte, platelet, hemoglobin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were analyzed. Overall survival (OS) and progression-free survival (PFS) were calculated. Significant prognostic factors were identified using univariate and multivariate analyses. RESULTS: The 5-year OS rate for all patients was 52.1% and 5-year PFS rate was 42.3%. Patients with mGPS of 0, 1 and 2 were 138, 71, 29, respectively. Higher mGPS was related to more advanced disease, including higher FIGO stage, lymph node metastases and lower lymphocyte counts, BMI and hemoglobin level. Performance status (PS), FIGO stage, lymph nodal status and mGPS were independent prognostic indicators for OS and PFS in the multivariate analysis. CONCLUSIONS: Higher mGPS is associated with advanced cervical cancer. The mGPS is an easily measurable biomarker which can be used in combination with conventional FIGO stage to predict survival in patients with cervical cancer undergoing chemoradiotherapy.
OBJECTIVES: There is increasing evidence that the presence of an inflammation-based prognostic score (modified Glasgow prognostic score, mGPS) could predict survival in patients with advanced cancer. The aim of this study was to investigate the prognostic value of mGPS in patients with cervical cancer. METHODS: We included 238 consecutive patients with cervical cancer in our study. The albumin and serum C-reactive protein (CRP) were measured before initiation of treatment. The relationships between the mGPS and other clinical parameters including body mass index (BMI), white blood cell count, lymphocyte, platelet, hemoglobin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were analyzed. Overall survival (OS) and progression-free survival (PFS) were calculated. Significant prognostic factors were identified using univariate and multivariate analyses. RESULTS: The 5-year OS rate for all patients was 52.1% and 5-year PFS rate was 42.3%. Patients with mGPS of 0, 1 and 2 were 138, 71, 29, respectively. Higher mGPS was related to more advanced disease, including higher FIGO stage, lymph node metastases and lower lymphocyte counts, BMI and hemoglobin level. Performance status (PS), FIGO stage, lymph nodal status and mGPS were independent prognostic indicators for OS and PFS in the multivariate analysis. CONCLUSIONS: Higher mGPS is associated with advanced cervical cancer. The mGPS is an easily measurable biomarker which can be used in combination with conventional FIGO stage to predict survival in patients with cervical cancer undergoing chemoradiotherapy.
Authors: Saskia C C M Teunissen; Wendy Wesker; Cas Kruitwagen; Hanneke C J M de Haes; Emile E Voest; Alexander de Graeff Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612
Authors: Stephan Polterauer; Christoph Grimm; Clemens Tempfer; Gerhard Sliutz; Paul Speiser; Alexander Reinthaller; Lukas A Hefler Journal: Gynecol Oncol Date: 2007-07-06 Impact factor: 5.482
Authors: Lukas A Hefler; Nicole Concin; Gerda Hofstetter; Christian Marth; Alexander Mustea; Jalid Sehouli; Robert Zeillinger; Heinz Leipold; Harald Lass; Christoph Grimm; Clemens B Tempfer; Alexander Reinthaller Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531